Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2007 Results
Date:11/8/2007

Submits Iloperidone New Drug Application (NDA); Begins Phase III Chronic Insomnia Study for VEC-162; Reports Results in VSF-173 Phase II Proof of

Concept Trial; Updates Full Year 2007 Financial Guidance

ROCKVILLE, Md., Nov. 8 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced financial and operational results for the third quarter ended September 30, 2007.

Vanda reported research and development (R&D) expenses in the third quarter of 2007 of $13.9 million, compared to second quarter of 2007 R&D expenses of $10.2 million and third quarter of 2006 R&D expenses of $9.5 million. The increase in R&D expenses in the third quarter of 2007 relative to the second quarter of 2007 is primarily attributable to a $5.0 million milestone charge resulting from the submission of the iloperidone NDA, which was partially offset by lower clinical trial costs associated with the completion of the long-term open label portion of the Phase III trial for iloperidone. The increase in R&D expenses in the third quarter of 2007 relative to the third quarter of 2006 was also primarily attributable to the $5.0 million NDA milestone charge, which was partially offset by lower clinical trial expenses for the company's iloperidone and VEC-162 Phase III trials that were primarily completed in 2006. Total expenses for the third quarter of 2007 were $23.5 million, compared to $17.6 million in the second quarter of 2007 and $12.8 million in the third quarter of 2006.

Net loss applicable to common stockholders was $21.9 million for the third
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that ... of Lixte,s lead compound, LB‑100, is being conducted, has been ... S. Kovach , M.D., the founder and President of Lixte, ... at a single site. Accrual of patients, however, was slower ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... of Directors has approved a share repurchase program. The ... $300 million of Mallinckrodt plc ordinary shares. ... opportunities remain top priorities as we continue to pursue ...
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held ... into an exclusive distributor agreement with ITOCHU Corporation (Tokyo ... therapy system for the treatment of cancer in ... system, is the world,s first and only MRI-guided radiation ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... DUBAI, UAE, February 8, 2012 In the ... diabetic; six countries in the MENA region are among the ... include the United Arab Emirates, Bahrain, Egypt, Kuwait, Oman and ... accounting for 14 percent of its total health care expenditure ...
... 7, 2012  Prometheus Laboratories Inc., a specialty pharmaceutical ... a research and collaboration agreement with an unnamed ... Prometheus, proprietary oncology diagnostic platform (CEER) to develop ... The CEER arrays may ultimately be used in ...
Cached Medicine Technology:Meeting of the Region's Top Diabetes Experts in Dubai this March 2Prometheus Signs Research & Collaboration Agreement with Leading Worldwide Pharmaceutical Company 2
(Date:1/22/2015)... 22, 2015 Woodloch Pines, an all-inclusive ... selected by TripAdvisor as the number one best large hotel ... in the world for their annual Travelers’ Choice Awards. ... . The website is home to millions of unbiased and ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 The Incredible ... Bodybuilder Ben Pakulski to increase lean muscle by up to ... has caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an ... that it is a step-by-step, scientific diet formula that allows ...
(Date:1/22/2015)... 2015 The federal court overseeing thousands of ... Court, Southern District of West Virginia has upheld a $2 ... first bellwether trial. In an Order dated January 21st, the ... finding that C.R. Bard had not proven a miscarriage of ...
(Date:1/22/2015)... 2015 Autocarinsurancebest.com has released a new blog ... auto insurance policy . , Auto insurance quotes help ... is no longer necessary to call an agent or visit ... online on a single website: http://autocarinsurancebest.com/ . , Every ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... back to the cancer communities in the cities visited ... Society for Therapeutic Radiology and Oncology (ASTRO) is partnering ... of cancer survivorship. The Kenneth B. Schwartz Center conducts ... the art of compassionate healthcare. , The Kenneth B. ...
... instances of Salmonella poisoning linked to a jalapeno pepper in Texas, ... sweating it out over the jalapeno crisis do not have to ... Resource reveals some fiery competition. , ... LENEXA, ...
... of articles and magazine covers talk about retirement, but the fact is ... By 2010, 58 million people--20% of the population--will be 50-64. ... survive and thrive in this challenging PreRetirement life stage? , ... (PRWEB) ...
... of Public Health Confirms Positive Review ... of DNA ... it received a formal letter from the California Department of Public,Health (CDPH) ... letter states that DNA Direct,s tests are,performed only with a physician order ...
... Inc. (Amex: ADK ), an Ohio based long ... refinancing of one of its nursing,homes in Ohio., ... single story nursing home,facility located in Greenfield, Ohio. Recently, ... of the art private bedrooms, along with a new,kitchen, ...
... Foundation to Provide Health Coverage Eligibility Screening and ... Application Assistance to Uninsured, ... wholly funded by WellPoint, Inc., has,awarded The CoverMe Foundation a ... in identifying and assisting uninsured persons,and families in finding and ...
Cached Medicine News:Health News: No More Jalapenos? No Problemo! Salmonella-Free Alternatives : No More Jalapenos? No Problemo, yes Poblano! 2Health News:Surviving Your PreRetirement Years: 15 Things You Must Do Between 50 and 64 2Health News:Surviving Your PreRetirement Years: 15 Things You Must Do Between 50 and 64 3Health News:Surviving Your PreRetirement Years: 15 Things You Must Do Between 50 and 64 4Health News:Surviving Your PreRetirement Years: 15 Things You Must Do Between 50 and 64 5Health News:Surviving Your PreRetirement Years: 15 Things You Must Do Between 50 and 64 6Health News:Surviving Your PreRetirement Years: 15 Things You Must Do Between 50 and 64 7Health News:DNA Direct Confirms It Is Operating in Compliance with California State Laboratory Law 2Health News:AdCare Health Systems, Inc. Announces the Refinancing of a Nursing Home in Ohio 2Health News:WellPoint Foundation Awards $2.5 Million Grant to The CoverMe Foundation 2Health News:WellPoint Foundation Awards $2.5 Million Grant to The CoverMe Foundation 3
... of the outstanding features of our Neomax ... Molding Technology. , This manufacturing process allows ... controls the bunching and irritation in the ... wearer. , ,Colors available: Blue, ...
... Flex™ might just be the world's most ... functional support, post-op/rehab support, or both, Flex ... new Accutrac™ ROM hinges control flexion and ... long-term durability while being heat-moldable to accommodate ...
... Donut is a neoprene alternative, constructed ... polyester Lycra Fabric that allows for ... provides for patellar control. Ideal for ... or irritations. Click here to view ...
... of the TROM provides the same easy ... as the full foam TROM, but is ... of use and versatility of the Cool ... following major ligament surgery, meniscal repairs, patella ...
Medicine Products: